| Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1 SAM Noureldien H. E. Darwish1,2, Thangirala Sudha2, Kavitha Godugu2, Osama ... Oncotarget, 2016 | 81 | 2016 |
| Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac T Sudha, DJ Bharali, M Yalcin, NHE Darwish, MD Coskun, KA Keating, ... Nanomedicine 12 (3), 195-205, 2017 | 60 | 2017 |
| Current status and future direction in the management of malignant melanoma P Gladfelter, NHE Darwish, SA Mousa Melanoma research 27 (5), 403-410, 2017 | 58 | 2017 |
| Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac. MSA Sudha T1, Bharali DJ1, Yalcin M2, Darwish NH3, Debreli Coskun M4 ... Int J Nanomedicine 12 (https://www.ncbi.nlm.nih.gov/pubmed/?ter), :1305-1315, 2017 | 54 | 2017 |
| Novel targeted nano-parthenolide molecule against NF-kB in acute myeloid leukemia NHE Darwish, T Sudha, K Godugu, DJ Bharali, O Elbaz, HAA El-ghaffar, ... Molecules 24 (11), 2103, 2019 | 52 | 2019 |
| A New Eucalyptol-Rich Lavender (Lavandula stoechas L.) Essential Oil: Emerging Potential for Therapy against Inflammation and Cancer MN Boukhatem, T Sudha, NHE Darwish, H Chader, A Belkadi, M Rajabi, ... Molecules 25 (16), 3671, 2020 | 45 | 2020 |
| Senescent colon and breast cancer cells induced by doxorubicin exhibit enhanced sensitivity to curcumin, caffeine, and thymoquinone AH El-Far, NHE Darwish, SA Mousa Integrative cancer therapies 19, 1534735419901160, 2020 | 44 | 2020 |
| Current and Future Molecular Targets for Acute Myeloid Leukemia Therapy. MSA Sami SA1, Darwish NHE1,2, Barile ANM1 Curr Treat Options Oncol 21 (3. doi: 10.1007/s11864-019-0694-6.), 2020 | 42 | 2020 |
| Nanoparticulate tetrac inhibits growth and vascularity of glioblastoma xenografts T Sudha, DJ Bharali, S Sell, NHE Darwish, PJ Davis, SA Mousa Hormones and Cancer 8, 157-165, 2017 | 40 | 2017 |
| Hepatitis C virus management: potential impact of nanotechnology MH Elberry, NHE Darwish, SA Mousa Virology Journal 14, 1-10, 2017 | 38 | 2017 |
| In Vitro Antifungal and Topical Anti-Inflammatory Properties of Essential Oil from Wild-Growing Thymus vulgaris (Lamiaceae) Used for Medicinal Purposes in … MN Boukhatem, NHE Darwish, T Sudha, S Bahlouli, D Kellou, ... Scientia Pharmaceutica 88 (3), 33, 2020 | 28 | 2020 |
| Synthesis of MR-49, a deiodinated analog of tetraiodothyroacetic acid (tetrac), as a novel pro-angiogenesis modulator M Rajabi, T Sudha, NHE Darwish, PJ Davis, SA Mousa Bioorganic & Medicinal Chemistry Letters 26 (16), 4112-4116, 2016 | 21 | 2016 |
| Nanonutraceuticals: Anti-cancer activity and improved safety of chemotherapy by costunolide and its nanoformulation against colon and breast cancer AH El-Far, K Godugu, TA Salaheldin, NHE Darwish, AA Saddiq, ... Biomedicines 9 (8), 990, 2021 | 14 | 2021 |
| Thymoquinone and its nanoformulation attenuate colorectal and breast cancers and alleviate doxorubicin-induced cardiotoxicity AH El-Far, TA Salaheldin, K Godugu, NHE Darwish, SA Mousa Nanomedicine 16 (17), 1457-1469, 2021 | 14 | 2021 |
| New Thyrointegrin αvβ3 Antagonist with a Scalable Synthesis, Brain Penetration, and Potent Activity against Glioblastoma Multiforme BA Hay, K Godugu, NHE Darwish, K Fujioka, T Sudha, OO Karakus, ... Journal of Medicinal Chemistry 64 (9), 6300-6309, 2021 | 13 | 2021 |
| Lactobacillus acidophilus and Bifidobacterium longum exhibit antiproliferation, anti-angiogenesis of gastric and bladder cancer: Impact of COX2 inhibition HG Nada, T Sudha, NHE Darwish, SA Mousa PharmaNutrition 14, 100219, 2020 | 13 | 2020 |
| Prognostic value of some inflammatory markers in patients with lymphoma N Hamed Anber, AH El-Sebaie, NHE Darwish, SA Mousa, SS Shamaa Bioscience Reports 39 (3), BSR20182174, 2019 | 12 | 2019 |
| Anticancer Effects of the Corchorus olitorius Aqueous Extract and Its Bioactive Compounds on Human Cancer Cell Lines JPS Tosoc, OM Nuñeza, T Sudha, NHE Darwish, SA Mousa Molecules 26 (19), 6033, 2021 | 11 | 2021 |
| Addition of Epigallocatechin gallate 400 mg to Sofosbuvir 400 mg+ Daclatisvir 60 mg with or without Ribavirin in treatment of patients with chronic Hepatitis C improves the … G Shiha, R Soliman, M Elbasiony, NHE Darwish, SA Mousa Scientific reports 9 (1), 13593, 2019 | 11 | 2019 |
| Anti-Angiogenesis Strategies in Cancer Therapies S Mousa, P Davis Academic Press, 2016 | 9 | 2016 |
Shaker MousaPresident, Vascular Vision Pharmaceuticals CoVerified email at vvpharma.com
